Preclinical and pharmacological investigations of ordonafil, a novel phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction

Preclinical and pharmacological investigations of ordonafil, a novel phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction

Bibliographic Details
Main Author:	Qinna, Nidal Adel
Published:	King's College London (University of London) 2005
Subjects:	616.6922061
Online Access:	http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.420646

Similar Items

Evolution of phosphodiesterase type 5 inhibitors in treatment of erectile dysfunction in Taiwan
by: Bang-Ping Jiann
Published: (2016-06-01)

Erectile dysfunction in patients taking psychotropic drugs and treated with phosphodiesterase-5 inhibitors
by: Rossella Mazzilli, et al.
Published: (2018-03-01)

Endothelial Dysfunction, Erectile Dysfunction and Phosphodiesterase 5 Inhibitors. An Update of the Current Data and Future Perspectives
by: Angelis Konstantinopoulos, et al.
Published: (2007-01-01)

Endothelial Dysfunction, Erectile Dysfunction and Phosphodiesterase 5 Inhibitors. An Update of the Current Data and Future Perspectives
by: Angelis Konstantinopoulos, et al.
Published: (2007-01-01)

Phosphodiesterase type 5 inhibitor (Levitra): possibility of correction of erectile dysfunction in obese patients
Published: (2008-03-01)

PHOSPHODIESTERASE-5 INHIBITORS USE IN PATIENTS WITH ERECTILE DYSFUNCTION AND CARDIOVASCULAR DISEASE IN CLINICAL PRACTICE
by: M. N. Mamedov, et al.
Published: (2016-01-01)

Correlations With Satisfaction Measures in Men Treated With Phosphodiesterase Inhibitors for Erectile Dysfunction
by: John P. Mulhall MD, et al.
Published: (2011-05-01)

Pathophysiology of visual disorders induced by phosphodiesterase inhibitors in the treatment of erectile dysfunction
by: Moschos MM, et al.
Published: (2016-10-01)

Oxidant stress, phosphodiesterase type 5 expression and erectile dysfunction
by: Hotston, Matthew R.
Published: (2010)

Non-invasive management of primary phosphodiesterase type 5 inhibitor failure in patients with erectile dysfunction
by: Gregory Lowe MD, et al.
Published: (2009-12-01)

Needs and Expectations of Patients with Erectile Dysfunction: An Update on Pharmacological Innovations in Phosphodiesterase Type 5 Inhibition with Focus on Sildenafil
by: Emmanuele A. Jannini, MD, et al.
Published: (2019-03-01)

Exercise training improves erectile dysfunction (ED) in patients with metabolic syndrome on phosphodiesterase-5 (PDE-5) inhibitors
by: Luigi Maresca, et al.
Published: (2013-12-01)

The design and synthesis of novel phosphodiesterase 4 inhibitors for the treatment of asthma
by: Irvine, Mark William
Published: (2007)

Acute effect of phosphodiesterase type 5 inhibitor on serum oxidative status and prolidase activities in men with erectile dysfunction
by: Murat Savas, et al.
Published: (2010-01-01)

High frequency of potential phosphodiesterase type 5 inhibitor drug interactions in males with HIV infection and erectile dysfunction.
by: Jason M Cota, et al.
Published: (2021-01-01)

Adherence to Phosphodiesterase Type 5 Inhibitors in the Treatment of Erectile Dysfunction in Long-Term Users: How Do Men Use the Inhibitors?
by: Ana Carvalheira, PhD, et al.
Published: (2014-06-01)

The Effect of Phosphodiesterase-type 5 Inhibitors on Erectile Function: An Overview of Systematic Reviews
by: Nikolaos Pyrgidis, et al.
Published: (2021-09-01)

A meta-regression evaluating the effectiveness and prognostic factors of oral phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction
by: Jin-Qiu Yuan, et al.
Published: (2016-01-01)

Patient preference and satisfaction in erectile dysfunction therapy: a comparison of the three phosphodiesterase-5 inhibitors sildenafil, vardenafil and tadalafil
by: Amr Abdel Raheem, et al.
Published: (2009-04-01)

Erectile dysfunction treatment with Phosphodiesterase-5 Inhibitors: Google trends analysis of last 10 years and COVID-19 pandemic
by: Müslim Dogan Değer, et al.
Published: (2021-10-01)

Preclinical pharmacological and toxicological study of novel inhibitory kappa B kinase alpha (IKKα) inhibitor compounds in prostate cancer
by: Alharbi, Khalid S.
Published: (2016)

Switching from Nitrate Therapy to Ranolazine in Patients with Coronary Artery Disease Receiving Phosphodiesterase Type-5 Inhibitors for Erectile Dysfunction
by: Dioma U. Udeoji, et al.
Published: (2014-01-01)

Switching from Nitrate Therapy to Ranolazine in Patients with Coronary Artery Disease Receiving Phosphodiesterase Type-5 Inhibitors for Erectile Dysfunction
by: Dioma U. Udeoji, et al.
Published: (2014-11-01)

Phosphodiesterase-5 inhibitors for erectile dysfunction in patients with diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials
by: Yatan Pal Singh Balhara, et al.
Published: (2015-01-01)

The role of phosphodiesterase 3, phosphodiesterase 5, and the inhibitory γ subunit of the retinal cyclic GMP phosphodiesterase, in pulmonary hypertension
by: Murray, Fiona
Published: (2003)

Clinical and preclinical treatment of urologic diseases with phosphodiesterase isoenzymes 5 inhibitors: an update
by: Wen-Hao Zhang, et al.
Published: (2016-01-01)

Experience of oxygen-ozonetherapy in the management of erectile dysfunction in diabetic patients poor responder to 5-phosphodiesterase inhibitors. Preliminary results and follow-up
by: F. Muzi, et al.
Published: (2020-10-01)

Comparative analysis on the efficacy of low-intensity shock wave treatment (Li-ESWT) and phosphodiesterase 5 inhibitor (PDE5i) for the treatment of erectile dysfunction
by: Y. Huang, et al.
Published: (2020-07-01)

MANAGEMENT OF ERECTILE DYSFUNCTION IN CARDIOVASCULAR PATIENTS WITH COMORBIDITIES: REVIEW OF THE TRIALS ON CONTINUING THERAPY WITH PHOSPHODIESTERASE-5 MEDICATIONS
by: G. G. Sharvadze, et al.
Published: (2018-06-01)

The role of advanced glycation end products in erectile dysfunction in diabetes
by: Cartledge, Jonathan James
Published: (2000)

The pharmacology of eltrombopag-dose selection in preclinical and clinical studies
by: Jenkins, Julian
Published: (2011)

Systematic review and meta-analysis of the use of phosphodiesterase type 5 inhibitors for treatment of erectile dysfunction following bilateral nerve-sparing radical prostatectomy.
by: Xiao Wang, et al.
Published: (2014-01-01)

Treatment satisfaction among men with concurrent benign prostatic hyperplasia and erectile dysfunction treated with tadalafil or other phosphodiesterase type-5 inhibitor combinations
by: Lee LK, et al.
Published: (2016-07-01)

The experiences of South Asian men with diabetes mellitus and erectile dysfunction
by: O'Brien, Chloe
Published: (2014)

Erectile disfunction medical treatment with phosphodiesterase 5 inhibitors (PDE5i) in patients with retinitis pigmentosa and side effects
by: Andrea Cocci, et al.
Published: (2020-12-01)

The preclinical and clinical pharmacology of novel histone deacetylase inhibitors
by: Kristeleit, Rebecca Sophie
Published: (2008)

An open-label, multicenter, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in Chinese men naïve to phosphodiesterase 5 inhibitor therapy
by: Wen-Jun Bai, et al.
Published: (2015-02-01)

Evaluation of pelvic floor muscle exercises and manometric biofeedback in the management of erectile dysfunction
by: Dorey, Grace Francis
Published: (2003)

Biochemical and biophysical investigations of novel phosphodiesterase-5 inhibitors
by: Shnoudeh, Abeer Jabra
Published: (2006)

Erectile dysfunction : is it really that difficult to talk about? : an interpretative phenomenological exploration
by: Dunn, Catherine
Published: (2016)